Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma.
The DOI matches its Crossref record.
Abstract
8512^ Background: Daratumumab (DARA) is a human CD38 monoclonal antibody (mAb) with broad-spectrum killing activity. Preliminary safety and efficacy data from this first-in-human dose-escalation study of DARA in pts with relapsed or refractory (RR) multiple myeloma (MM) have previously been published. Here, we present safety and efficacy data from the finalized part 1 and preliminary safety data from the ongoing part 2 of the study. Methods: Pts ≥18 years requiring systemic therapy and considered RR to at least 2 prior lines of therapy and ineligible for ASCT were enrolled. In part 1, a 3+3 dose-escalation design was applied and DARA was administered over a 9-week period as 2 pre- and 7 full doses. The phase II dose was determined to 8mg/kg and these pts receive DARA weekly for 8 weeks followed by dosing every 2nd week for 16 weeks and every 4th week until disease progression, toxicity or for max. 24 months. Results: Data from 32 pts included in part 1 are presented. In part 2, 7/16 pts have been recruited: all available data will be presented at the meeting. In part 1, the median number of prior treatment lines was 6. PK analysis showed plasma peak levels as expected but relatively rapid clearance at low dose levels. At doses ≥4mg/kg, observed PK values approximated model-predicted values. Efficacy evaluation from part 1 was based on IMWG guidelines. In the ≥4mg/kg groups (n=12), 5 PRs and 3 MRs were observed. 7 of these pts had a 50-100% concomitant reduction in bone marrow plasma cells. Median PFS in the ≥4mg/kg dose groups was not reached (median follow-up at data cut-off was 3.8mths (range: 0-9.6mths). No ADA responses were detected. In part 1, the most common adverse events reported were infusion related (IRE) which occurred predominantly during the first full infusion. 44% of subjects across all dose groups had IREs grade 1-3, of which 2 were grade 3. Six related SAEs (1 anemia, 1 thrombocytopenia, 2 bronchospasm, 1 cytokine release, 1 AST increase) were reported. Conclusions: DARA induced a marked reduction in paraprotein and bone marrow plasma cells at doses ≥4mg/kg in heavily pretreated RR MM pts. In addition, high response rates and encouraging PFS data were observed. This is unprecedented for single-agent mAb treatment of MM. Clinical trial information: NCT00574288.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Resolving the daratumumab interference with blood compatibility testing
Chapuy, C. I., Nicholson, R. T., Aguad, M. D., Chapuy, B., Laubach, J. P., Richardson, P. G., Doshi, P., & Kaufman, R. M. (2015) · Transfusion · doi:10.1111/trf.13069 · Cited by 239
Self-citationHaematological malignancies: at the forefront of immunotherapeutic innovation
Bachireddy, P., Burkhardt, U. E., Rajasagi, M., & Wu, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3907 · Cited by 85
Treatment-related symptom management in patients with multiple myeloma: a review
Colson, K. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-014-2552-1 · Cited by 51
Metadata
- Authors
- Lokhorst, H. M., Plesner, T., Gimsing, P., Nahi, H., Minnema, M., Lassen, U. N., Krejcik, J., Laubach, J., Lisby, S., Basse, L., & Richardson, P. G. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-05-20
- Volume
- 31
- Issue
- 15_suppl
- Pages
- 8512-8512
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2599394621
- Cited by
- 36
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma. https://app.cochat.ai/papers/10.1200/jco.2013.31.15_suppl.8512
- The paper
- Lokhorst, H. M., Plesner, T., Gimsing, P., Nahi, H., Minnema, M., Lassen, U. N., Krejcik, J., Laubach, J., Lisby, S., Basse, L., & Richardson, P. G. G. (2013). Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2013.31.15_suppl.8512
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.